Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
WALTHAM, Mass., March 05, 2018 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in the following investor conferences:
- Cowen and Company 38th Annual Health Care Conference
Monday, March 12, 2018 at 1:30 p.m. ET
Location: Boston, MA - Barclays Global Healthcare Conference
Wednesday, March 14, 2018 at 3:50 p.m. ET
Location: Miami, FL - Needham 17th Annual Healthcare Conference
Tuesday, March 27, 2018 at 8:30 a.m. ET
Location: New York, NY
To access the live webcasts, please visit the Investors section of the company’s website at www.amagpharma.com. A replay of each event will be archived on the site for 30 days.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of maternal and women’s health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. CBR® is a registered trademark of Cbr Systems, Inc.
AMAG Pharmaceuticals Contact:
Christi Waarich
Associate Director, Investor Relations
617-498-7638
